-
Views
-
Cite
Cite
S. Parish, J. Simon, B. Lynn, B. Bernick, S. Mirkin, R. Sitruk-Ware, 015 Evidence of Low Androgenicity and Little Impact on Sexual Function or Activity with Annovera™, a Novel Contraceptive Vaginal System Releasing Segesterone Acetate and Ethinyl Estradiol, The Journal of Sexual Medicine, Volume 16, Issue Supplement_3, June 2019, Pages S7–S8, https://doi.org/10.1016/j.jsxm.2019.03.472
Close - Share Icon Share
Extract
Introduction
Combined hormonal contraceptives (CHCs) may impact sexual function, in part due to interaction of the progestin component with the androgen receptor (AR). Previous reports on the effect of hormonal contraceptives on libido have been mixed, some showing decreases and others showing increases in libido. Annovera™, a 1-year contraceptive vaginal system (CVS) releasing 150 mcg segesterone acetate (SA) and 13 mcg ethinyl estradiol (EE) per day, was recently approved by the US Food and Drug Administration (August 2018).
Objective
To review evidence from preclinical studies investigating the androgenicity of the SA component of the CVS, and data on its effects on sexual function or activity in women.
Methods
We reviewed articles on studies that measured markers of androgenicity of SA and those that examined sexual function/activity in those using SA/EE CVS. Some aspects of sexual function and activity were assessed via a questionnaire completed by participants in an international phase 3, open-label, multi-center, 13-cycle trial evaluating the efficacy and safety of the SA/EE CVS.1,2 Participants completed the questionnaire at cycle 3 of CVS use and/or at study end; cycle 3 was used if end of study was not completed.
